Introduction The development of an effective vaccine to protect against HIV is a longstanding
global health need complicated by challenges inherent to HIV biology and to the execution …

The development of an effective vaccine has been hindered by the enormous diversity of
human immunodeficiency virus‐1 (HIV‐1) and its ability to escape a myriad of host immune …

Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX …

This book builds on and is a sequel to our book Targeted Learning: Causal Inference for
Observational and Experimental Studies (2011). Since the publication of this first book on …

Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …

While antibody titers and neutralization are considered the gold standard for the selection of
successful vaccines, these parameters are often inadequate predictors of protective …

HIV-1–specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc
receptors. Antibodies of the same epitope specificity but of a different subclass therefore can …

The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in
Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By contrast …

Antiretroviral drug therapy (ART) effectively suppresses replication of both the
immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon …

The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with …